KR100975782B1 - 플루바스타틴 나트륨의 결정 형태 - Google Patents

플루바스타틴 나트륨의 결정 형태 Download PDF

Info

Publication number
KR100975782B1
KR100975782B1 KR1020047001615A KR20047001615A KR100975782B1 KR 100975782 B1 KR100975782 B1 KR 100975782B1 KR 1020047001615 A KR1020047001615 A KR 1020047001615A KR 20047001615 A KR20047001615 A KR 20047001615A KR 100975782 B1 KR100975782 B1 KR 100975782B1
Authority
KR
South Korea
Prior art keywords
fluvastatin sodium
crystalline polymorph
relative humidity
characteristic
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047001615A
Other languages
English (en)
Korean (ko)
Other versions
KR20040022226A (ko
Inventor
판데어샤프폴아드리안
마르콜리클라우디아
첼라기비츠마르틴
부르크하르트안드레아스
볼렙하인쯔
볼렙안네마리
Original Assignee
시바 홀딩 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시바 홀딩 인크 filed Critical 시바 홀딩 인크
Publication of KR20040022226A publication Critical patent/KR20040022226A/ko
Application granted granted Critical
Publication of KR100975782B1 publication Critical patent/KR100975782B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
KR1020047001615A 2001-08-03 2002-07-25 플루바스타틴 나트륨의 결정 형태 Expired - Fee Related KR100975782B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01810756.5 2001-08-03
EP01810756 2001-08-03
PCT/EP2002/008276 WO2003013512A2 (en) 2001-08-03 2002-07-25 Crystalline forms of fluvastatin sodium

Publications (2)

Publication Number Publication Date
KR20040022226A KR20040022226A (ko) 2004-03-11
KR100975782B1 true KR100975782B1 (ko) 2010-08-17

Family

ID=8184071

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047001615A Expired - Fee Related KR100975782B1 (ko) 2001-08-03 2002-07-25 플루바스타틴 나트륨의 결정 형태

Country Status (16)

Country Link
US (1) US6696479B2 (enExample)
EP (1) EP1429757B8 (enExample)
JP (2) JP4681808B2 (enExample)
KR (1) KR100975782B1 (enExample)
CN (2) CN1536999B (enExample)
AR (1) AR036205A1 (enExample)
AT (1) ATE391502T1 (enExample)
AU (1) AU2002333271B2 (enExample)
CA (1) CA2454072A1 (enExample)
DE (1) DE60226044T2 (enExample)
ES (1) ES2304140T3 (enExample)
HU (1) HUP0401141A3 (enExample)
IL (2) IL159861A0 (enExample)
PL (1) PL366905A1 (enExample)
RU (1) RU2334738C2 (enExample)
WO (1) WO2003013512A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
AU2003250086A1 (en) * 2002-07-26 2004-02-23 Ciba Specialty Chemicals Holging Inc. Crystalline polymorphic and amorphous forms of benazepril hydrochloride
WO2004096765A2 (en) * 2003-05-01 2004-11-11 Morepen Laboratories Ltd. A novel crystalline polymorph of fluvastatin sodium and a process for preparing it
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
EP1638937B1 (en) * 2003-06-18 2008-12-17 Teva Pharmaceutical Industries Limited Fluvastatin sodium crystal form xiv, processes for preparing it, compositions containing it and methods of using it
US7368581B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
US7892354B2 (en) * 2003-10-06 2011-02-22 Solvias Ag Process for the parallel detection of crystalline forms of molecular solids
WO2005037787A1 (en) * 2003-10-16 2005-04-28 Ciba Specialty Chemicals Holding Inc. Crystalline form of fluvastatin sodium
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
WO2005080332A1 (en) * 2004-01-14 2005-09-01 Cadila Healthcare Limited Novel form of fluvastatin sodium
WO2005075467A2 (en) * 2004-02-06 2005-08-18 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
WO2006021967A1 (en) * 2004-08-26 2006-03-02 Biocon Limited Process for the preparation of fluvastatin sodium form a.
WO2006030304A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
WO2006085338A2 (en) * 2005-02-11 2006-08-17 Jubilant Organosys Limited Novel polymorphic forms of fluvastatin sodium and process for preparing the same
WO2006109147A1 (en) * 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
WO2007039784A2 (en) * 2005-10-06 2007-04-12 Wockhardt Limited A novel crystalline polymorph of fluvastatin sodium and process for preparing it
WO2007054951A1 (en) * 2005-11-14 2007-05-18 Hetero Drugs Limited Process for amorphous esomeprazole
TW200804279A (en) * 2006-02-27 2008-01-16 Teva Pharma Fluvastatin sodium novel forms and preparation thereof
WO2009122425A1 (en) * 2008-04-04 2009-10-08 Shodhana Laboratories Limited Novel crystalline form of carvedilol dihydrogen phosphate and related processes
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
JP6115288B2 (ja) * 2012-04-27 2017-04-19 株式会社島津製作所 質量分析におけるピーク検出方法及びそのシステム
TW201806928A (zh) * 2016-07-01 2018-03-01 第一三共股份有限公司 胺基羧酸之酸加成鹽的結晶及其製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003958A1 (en) 1995-07-17 1997-02-06 Warner-Lambert Company Form iii crystalline (r-(r*,r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
US6124340A (en) * 1996-06-24 2000-09-26 Astra Aktiebolag Polymorphic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU204253B (en) * 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
PH23486A (en) * 1982-11-22 1989-08-16 Sanzoz Inc Indole analogs of mevalonolactone,pharmaceutical compositions containing the same and method of use thereof
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
ES2247193T3 (es) * 2000-10-31 2006-03-01 Ciba Specialty Chemicals Holding Inc. Formas cristalinas del fluvastatin sodico.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003958A1 (en) 1995-07-17 1997-02-06 Warner-Lambert Company Form iii crystalline (r-(r*,r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
US6124340A (en) * 1996-06-24 2000-09-26 Astra Aktiebolag Polymorphic compounds

Also Published As

Publication number Publication date
AU2002333271B2 (en) 2007-08-09
ATE391502T1 (de) 2008-04-15
DE60226044D1 (de) 2008-05-21
US6696479B2 (en) 2004-02-24
CN1536999B (zh) 2012-08-08
CA2454072A1 (en) 2003-02-20
US20030032666A1 (en) 2003-02-13
ES2304140T3 (es) 2008-09-16
WO2003013512A2 (en) 2003-02-20
HUP0401141A2 (hu) 2004-09-28
KR20040022226A (ko) 2004-03-11
IL159861A0 (en) 2004-06-20
CN102516150A (zh) 2012-06-27
JP2005501838A (ja) 2005-01-20
EP1429757B1 (en) 2008-04-09
IL159861A (en) 2009-02-11
HUP0401141A3 (en) 2011-07-28
EP1429757A2 (en) 2004-06-23
EP1429757B8 (en) 2008-07-16
DE60226044T2 (de) 2009-05-14
WO2003013512A3 (en) 2003-11-20
AR036205A1 (es) 2004-08-18
JP4681808B2 (ja) 2011-05-11
JP2010265308A (ja) 2010-11-25
PL366905A1 (en) 2005-02-07
RU2334738C2 (ru) 2008-09-27
RU2004106528A (ru) 2005-07-27
CN1536999A (zh) 2004-10-13

Similar Documents

Publication Publication Date Title
KR100975782B1 (ko) 플루바스타틴 나트륨의 결정 형태
AU2002333271A1 (en) Crystalline forms of fluvastatin sodium
US6858643B2 (en) Crystalline forms of Fluvastatin sodium
US4721723A (en) Anti-depressant crystalline paroxetine hydrochloride hemihydrate
US4739055A (en) Anhydrous, stable, crystalline δ-form of prazosin hydrochloride
AU700545B2 (en) Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
JP2004513106A (ja) 塩酸ベンラファキシンの結晶形
WO2002050036A1 (en) Crystalline forms of cerivastatin sodium
US4067867A (en) Process for preparing pyrazine precursor of methotrexate or an N-substituted derivative thereof and/or a di(lower)alkyl ester thereof
US6521760B1 (en) Process for the preparation of zofenopril calcium salt
CA2082472A1 (en) Crystalline form of a cephalosporin antibiotic
AU764154B2 (en) Method for producing (-)-alpha-(difluoromethyl)ornithine-monohydrochloride monohydrate
NZ531993A (en) New anhydrous crystalline forms of gabapentin
EP0327081A2 (en) Alpha-crystals of cefazolin sodium
Barger et al. XXX.—The alkaloids of ergot. Part II
Wilson et al. CCLXXI.—Contributions to our knowledge of semicarbazones. Part IV. Action of hydrogen chloride
JPWO2003072587A1 (ja) 不揮発性チアゾリジン化合物の製造方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130810

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130810